One in eight women affected

Polyendrocrine Metabolic Ovarian Syndrome, formerly known as polycystic ovarian syndrome, affects one in eight women. Symptoms include irregular periods, excess hair growth, weight gain and hair thinning.

Lifelong condition with serious risks

PMOS is a lifelong condition with no cure. It can lead to an increased risk of type two diabetes, cardiovascular disease and endometrial cancer.

Advocates push for PBS funding

The Polyendrocrine Metabolic Ovarian Syndrome Association of Australia is urging for GLP-1 drugs to be approved on the Pharmaceutical Benefits Scheme for people living with the condition.

Cost barrier keeps women away

Lorna Berry, a POSAA spokesperson diagnosed at thirty-two, said some women were missing out on accessing GLP-1 medications due to high costs, which can set patients back several hundred dollars each month.

“It's important for people to have access to medications, irrespective of where they live or where they were born.”

Experts warn of obstacles

Associate professor Magdalena Simonis said GLP-1s are not the only treatment available and long-term use is expensive. She said they are unlikely to be on the PBS anytime soon, maybe not ever for PMOS.

“Because traditionally women's conditions are not included in these changes.”

Committee to reconsider Wegovy listing

The Pharmaceutical Benefits Advisory Committee will meet next month to consider Novo Nordisk's revised proposal to list Wegovy for obesity following protracted negotiations. Novo Nordisk produces both Ozempic and Wegovy.